WO2015091992A1 - Pharmaceutical composition comprising amorphous ivabradine - Google Patents
Pharmaceutical composition comprising amorphous ivabradine Download PDFInfo
- Publication number
- WO2015091992A1 WO2015091992A1 PCT/EP2014/078819 EP2014078819W WO2015091992A1 WO 2015091992 A1 WO2015091992 A1 WO 2015091992A1 EP 2014078819 W EP2014078819 W EP 2014078819W WO 2015091992 A1 WO2015091992 A1 WO 2015091992A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- ivabradine
- acceptable salt
- solid composite
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Definitions
- the compound is a pharmaceutically active compound used for the treatment of stable angina pectoris and chronic heart failure.
- the compound was discovered by Adir and is disclosed in EP534859.
- the compound may form acid addition salts, for instance Ivabradine
- hydrochloride which is the active ingredient in the medicinal product sold under the brand name Corlentor® and Procoralan® by Laboratoires Servier.
- Ivabradine hydrochloride exhibits polymorphism.
- WO2006092493 discloses polymorph ⁇ of ivabradine hydrochloride, its process of preparation and compositions comprising this polymorph. Polymorph ⁇ is the most stable form and is present in the marketed product.
- Other polymorphic forms of ivabradine hydrochloride are disclosed in WO2005110993, WO2006092491, WO2006092492, WO2006092494, WO2007042656, WO2007042657 and WO2013064307. The prior art thus teaches that ivabradine
- hydrochloride crystallizes very easily. Moreover, it was experienced in our laboratory that polymorphic transitions of ivabradine hydrochloride take place rather easily, especially in pharmaceutical composition. Amorphous ivabradine hydrochloride and methods for its preparation are disclosed in WO2008146308, CN101597261 and CN101463008. We observed in our laboratory that amorphous ivabradine hydrochloride is very hygroscopic and is therefore not suitable for use on pharmaceutical production scale.
- compositions comprising ivabradine, or a pharmaceutically acceptable salt thereof, which are stable and suitable for use on a commercial scale.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co-) polymer and one or more pharmaceutically acceptable excipients, wherein ivabradine, or a pharmaceutically acceptable salt thereof, is in an amorphous form.
- the invention provides a process for preparing said pharmaceutical composition comprising mixing or granulating said solid composite with one or more excipients, followed by compression into tablets.
- Said pharmaceutical composition may be used as a medicament, particularly in the treatment of stable angina pectoris and chronic heart failure.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients, wherein ivabradine, or a pharmaceutically acceptable salt thereof, is in an amorphous form.
- ivabradine, or a pharmaceutically acceptable salt thereof, and the acrylate (co)polymer are preferably intimately associated, meaning that there is attractive interaction between the active pharmaceutical ingredient and the (co)polymer.
- the weight ratio of ivabradine, or a pharmaceutically acceptable salt thereof, to (co)polymer in the solid composite typically ranges from 1: 1 to 1:8, preferably from 1: 1 to 1:3.
- the acrylate (co)polymer is a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate with a ratio of 2: 1 : 1.
- Typical examples of such a commercially available cationic copolymer are Eudragit® E PO, Eudragit® E 100 and Eudragit® E 12,5.
- the acrylate (co)polymer is a copolymer of methacrylic acid and divinylbenzene, and is known under the international nonproprietary name (INN) polacrilex or polacrilin resin.
- INN international nonproprietary name
- the carboxylic acid groups of the polacrilex resin are in the H+ form, while the polacrilin resin is supplied as the potassium salt.
- Typical examples of commercially available polacrilex resins include
- Amberlite® IRP64 and Indion® 214 examples of commercially available polacrilin resins include Amberlite® IRP88 and Indion® 294.
- At least a major portion of ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is amorphous.
- the term "a major portion" of ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is amorphous.
- ivabradine, or a pharmaceutically acceptable salt thereof means that at least 60% of the drug is in amorphous form, rather than a crystalline form.
- ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is substantially amorphous.
- substantially amorphous means that the amount of ivabradine, or a pharmaceutically acceptable salt thereof, in amorphous form is at least 80%.
- ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is "almost completely amorphous” meaning that the amount of ivabradine, or a pharmaceutically acceptable salt thereof, in the amorphous form is at least 90% as measured by powder X-ray diffraction or any other standard quantitative measurement.
- ivabradine, or a pharmaceutically acceptable salt thereof means that at least 60% of the drug is in amorphous form, rather than a crystalline form.
- ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is substantially amorphous.
- the solid composite in accordance with the present invention advantageously is in the form of a free-flowing powder, with excellent handling properties and stable morphology.
- the solid composite is very suitable to be used for the preparation of pharmaceutical compositions.
- compositions of the present invention comprise the solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients.
- the excipients to be used in accordance with the present invention are well-known and are those excipients which are conventionally used by the person skilled in the art.
- the dosage form chosen for the pharmaceutical composition the person skilled in the art will be able to select suitable pharmaceutically acceptable excipients.
- the dosage form is an immediate-release tablet and the pharmaceutically acceptable excipients are chosen from one or more binders, diluents, disintegrants, glidants, lubricants, stabilizers, surface active agents or pH-adjusting agents.
- compositions of the present invention display dissolution behavior typical for immediate-release formulations.
- compositions of the present invention, ivabradine, or a pharmaceutically acceptable salt thereof remains in the amorphous form.
- the present invention further provides a process to prepare a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer, comprising combining the (co)polymer with ivabradine, or a pharmaceutically acceptable salt thereof, in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s), using equipment and methods well-known in the art.
- isolation of the solid composite may also be established by filtration.
- the solvent or solvent mixture is water, a polar organic solvent or a mixture of water and a polar organic solvent.
- ivabradine, or a pharmaceutically acceptable salt thereof is dissolved in a polar organic solvent, water or a mixture of water and a polar organic solvent and the acrylate (co)polymer is added to this solution.
- Preferred polar organic solvents are alcohols, particularly ethanol or methanol, ethers, particularly tetrahydrofuran, ketones, particularly acetone and acetonitrile.
- an alcohol, water or a mixture of an alcohol and water is used.
- the present invention still further provides a process to prepare pharmaceutical compositions comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients.
- the process comprises mixing or granulating the solid composite with one or more pharmaceutically acceptable excipients, followed by compression into tablets, using equipment and methods well-known to the skilled artisan.
- the composite, in solution was spray-dried onto one of the main excipients, e.g. the diluent, and the resulting granulate/blend was mixed with one or more pharmaceutically acceptable excipients, followed by compression into tablets.
- the pharmaceutical composition in accordance with the present invention may be used as a medicament.
- the pharmaceutical composition typically may be used in the treatment of stable angina pectoris and chronic heart failure.
- the present invention is illustrated by the following Examples.
- Example 1 ivabradine hydrochloride: Eudragit® E PO (weight ratio 1:1)
- ivabradine hydrochloride was dissolved in 41.50 g of ethanol (96%). 5.16 g of Eudragit® E PO was added. The solution was spray-dried on 134.43 g of microcrystalline cellulose. The resulting granulate/blend was sieved and 4.50 g of croscarmellose sodium was added by mixing, followed by the addition of 0.75 g magnesium stearate. The powder blend was compacted into tablets. Tablets with a total weight of 240 mg, containing 7.5 mg of ivabradine (referring to the amount of free base) were obtained.
- the XRPD patterns of the tablets do not show any reflections in accordance with crystalline ivabradine hydrochloride.
- XRPD analysis performed 1 week after subjecting the tablets in open dish to 55°C/90% RH and 1 month to 40°C /75% RH showed that the tablets still do not show any reflections in accordance with crystalline ivabradine hydrochloride.
- Tablets showed a fast dissolution at pH 1.2, 4.5 and 6.8.
- Example 2 ivabradine hydrochloride: Eudragit® E PO (weight ratio 1:2)
- ivabradine hydrochloride was dissolved in 75.00 g of ethanol (96%). 10.33 g of Eudragit® E PO was added. The solution was spray-dried on 129.26 g of microcrystalline cellulose. The resulting granulate/blend was sieved and 4.50 g of croscarmellose sodium was added by mixing, followed by the addition of 0.75 g magnesium stearate. The powder blend was compacted into tablets. Tablets with a total weight of 240 mg, containing 7.5 mg of ivabradine (referring to the amount of free base) were obtained.
- the XRPD patterns of the tablets do not show any reflections in accordance with crystalline ivabradine hydrochloride.
- XRPD analysis performed 1 week after subjecting the tablets in open dish to 55°C/90 RH and 1 month in alu/alu packaging to 40°C /75 RH showed that the tablets still do not show any reflections in accordance with crystalline ivabradine hydrochloride.
- ivabradine hydrochloride was dissolved in 185.00 g of ethanol (96%). 25.80 g of Eudragit® E PO was added. The solution was spray-dried on 113.81 g of microcrystalline cellulose. The resulting granulate/blend was sieved and 4.50 g of croscarmellose sodium was added by mixing, followed by the addition of 0.75 g magnesium stearate. The powder blend was compacted into tablets. Tablets with a total weight of 240 mg, containing 7.5 mg of ivabradine (referring to the amount of free base) were obtained.
- the XRPD patterns of the tablets do not show any reflections in accordance with crystalline ivabradine hydrochloride.
- XRPD analysis performed 1 week after subjecting the tablets in open dish to 55°C/90% RH and 1 month to 40°C /75% RH showed that the tablets still do not show any reflections in accordance with crystalline ivabradine hydrochloride.
- Tablets showed a fast dissolution at pH 4.5 and 6.8.
- the composites were prepared by making a slurry of ivabradine hydrochloride and Amberlite® in water. The pH of the slurry was adjusted with either 0.1 M aqueous sodium hydroxide or 2.0 M aqueous hydrochloride to either 4-5 or 6-8 (see table 1). The slurries were stirred at ambient temperature over night. The composite was isolated by filtration, washed with water and dried at air.
- Example 4 ivabradine hydrochloride: Amberlite® IRP64 (weight ratio 1:3)
- Tablets were prepared with the ivabradine hydrochloride:Amberlite® IRP64 (weight ratio 1:3) solid composite, obtained as described in example 3. The composition of the tablets is shown in table 2.
- Ivabradine hydrochloride Amberlite® IRP64 (weight ratio 1:3) 15.0
- Lactose monohydrate granulate (Supertab 30 GR) 64.0
- the solid composite of ivabradine hydrochloride Amberlite® IRP64 (weight ratio 1:3) was mixed with Aerosil 200 VV and part of the lactose monohydrate granulate (Supertab 30 GR) for 10 minutes in a Turbula mixer at 22 rpm. The pre-mix was sieved over a 0.5 mm sieve. Pregelatinized starch (Starch 1500) and the rest of the lactose monohydrate granulate (Supertab 30 GR) were added and mixing was continued for 10 minutes. Magnesium stearate was sieved over a 0.6 mm sieve, added and mixed for 3 minutes at 22 rpm. Tablets were compressed.
Abstract
The present invention relates to a pharmaceutical composition comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients, wherein ivabradine, or a pharmaceutically acceptable salt thereof, is in an amorphous form. The invention further relates to the use of said composition as a medicament, particularly in the treatment of stable angina pectoris and chronic heart failure.
Description
PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS
IVABRADINE
BACKGROUND OF THE PRESENT INVENTION
Ivabradine, chemically 3-(3-{ [((7S)-3,4-dimethoxybicyclo[4.2.0]octa- l,3,5-trien-7- yl)methyl]methylamino }propyl)-7,8-dimethoxy- l,3,4,5-tetrahydro-2H-3-benzazepin-2-one formula (I),
(I)
is a pharmaceutically active compound used for the treatment of stable angina pectoris and chronic heart failure. The compound was discovered by Adir and is disclosed in EP534859. The compound may form acid addition salts, for instance Ivabradine
hydrochloride, which is the active ingredient in the medicinal product sold under the brand name Corlentor® and Procoralan® by Laboratoires Servier.
Ivabradine hydrochloride exhibits polymorphism. WO2006092493 discloses polymorph β of ivabradine hydrochloride, its process of preparation and compositions comprising this polymorph. Polymorph β is the most stable form and is present in the marketed product. Other polymorphic forms of ivabradine hydrochloride are disclosed in WO2005110993, WO2006092491, WO2006092492, WO2006092494, WO2007042656, WO2007042657 and WO2013064307. The prior art thus teaches that ivabradine
hydrochloride crystallizes very easily. Moreover, it was experienced in our laboratory that polymorphic transitions of ivabradine hydrochloride take place rather easily, especially in pharmaceutical composition.
Amorphous ivabradine hydrochloride and methods for its preparation are disclosed in WO2008146308, CN101597261 and CN101463008. We observed in our laboratory that amorphous ivabradine hydrochloride is very hygroscopic and is therefore not suitable for use on pharmaceutical production scale.
Thus in view of the prior art cited above, there is still a need for pharmaceutical compositions comprising ivabradine, or a pharmaceutically acceptable salt thereof, which are stable and suitable for use on a commercial scale.
BRIEF DESCRIPTION OF THE PRESENT INVENTION
The present invention provides a pharmaceutical composition comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co-) polymer and one or more pharmaceutically acceptable excipients, wherein ivabradine, or a pharmaceutically acceptable salt thereof, is in an amorphous form.
It also provides a process for preparing said solid composite by combining ivabradine, or a pharmaceutically acceptable salt thereof, with an acrylate (co)polymer in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s).
Additionally, the invention provides a process for preparing said pharmaceutical composition comprising mixing or granulating said solid composite with one or more excipients, followed by compression into tablets.
Said pharmaceutical composition may be used as a medicament, particularly in the treatment of stable angina pectoris and chronic heart failure.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
The present invention relates to a pharmaceutical composition comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate
(co)polymer and one or more pharmaceutically acceptable excipients, wherein ivabradine, or a pharmaceutically acceptable salt thereof, is in an amorphous form.
In the solid composite, ivabradine, or a pharmaceutically acceptable salt thereof, and the acrylate (co)polymer are preferably intimately associated, meaning that there is attractive interaction between the active pharmaceutical ingredient and the (co)polymer. The weight ratio of ivabradine, or a pharmaceutically acceptable salt thereof, to (co)polymer in the solid composite typically ranges from 1: 1 to 1:8, preferably from 1: 1 to 1:3.
In a preferred embodiment of the invention, the acrylate (co)polymer is a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate with a ratio of 2: 1 : 1. Typical examples of such a commercially available cationic copolymer are Eudragit® E PO, Eudragit® E 100 and Eudragit® E 12,5.
In another preferred embodiment of the invention, the acrylate (co)polymer is a copolymer of methacrylic acid and divinylbenzene, and is known under the international nonproprietary name (INN) polacrilex or polacrilin resin. Typically, the carboxylic acid groups of the polacrilex resin are in the H+ form, while the polacrilin resin is supplied as the potassium salt. Typical examples of commercially available polacrilex resins include
Amberlite® IRP64 and Indion® 214. Examples of commercially available polacrilin resins include Amberlite® IRP88 and Indion® 294.
At least a major portion of ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is amorphous. The term "a major portion" of ivabradine, or a
pharmaceutically acceptable salt thereof, means that at least 60% of the drug is in amorphous form, rather than a crystalline form. Preferably, ivabradine, or a pharmaceutically acceptable salt thereof, in the solid composite is substantially amorphous. As used herein, "substantially amorphous" means that the amount of ivabradine, or a pharmaceutically acceptable salt thereof, in amorphous form is at least 80%. More preferably, ivabradine, or a
pharmaceutically acceptable salt thereof, in the solid composite is "almost completely amorphous" meaning that the amount of ivabradine, or a pharmaceutically acceptable salt thereof, in the amorphous form is at least 90% as measured by powder X-ray diffraction or any other standard quantitative measurement. Most preferably, ivabradine, or a
pharmaceutically acceptable salt thereof, in the solid composite is in a completely amorphous form within the detection limits of the techniques used for characterization.
The solid composite in accordance with the present invention advantageously is in the form of a free-flowing powder, with excellent handling properties and stable morphology. The solid composite is very suitable to be used for the preparation of pharmaceutical compositions.
The pharmaceutical compositions of the present invention comprise the solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients. The excipients to be used in accordance with the present invention are well-known and are those excipients which are conventionally used by the person skilled in the art. Depending on the dosage form chosen for the pharmaceutical composition, the person skilled in the art will be able to select suitable pharmaceutically acceptable excipients. Preferably, the dosage form is an immediate-release tablet and the pharmaceutically acceptable excipients are chosen from one or more binders, diluents, disintegrants, glidants, lubricants, stabilizers, surface active agents or pH-adjusting agents.
The pharmaceutical compositions of the present invention display dissolution behavior typical for immediate-release formulations. During preparation and storage of the
pharmaceutical compositions of the present invention, ivabradine, or a pharmaceutically acceptable salt thereof, remains in the amorphous form.
The present invention further provides a process to prepare a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer, comprising combining the (co)polymer with ivabradine, or a pharmaceutically acceptable salt thereof, in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s), using equipment and methods well-known in the art. Alternatively, isolation of the solid composite may also be established by filtration.
Preferably, the solvent or solvent mixture is water, a polar organic solvent or a mixture of water and a polar organic solvent. In an advantageous variant of the process of the present invention, ivabradine, or a pharmaceutically acceptable salt thereof, is dissolved in a polar organic solvent, water or a mixture of water and a polar organic solvent and the acrylate (co)polymer is added to this solution. Preferred polar organic solvents are alcohols, particularly ethanol or methanol, ethers, particularly tetrahydrofuran, ketones, particularly acetone and acetonitrile. Preferably, an alcohol, water or a mixture of an alcohol and water is used.
The present invention still further provides a process to prepare pharmaceutical compositions comprising a solid composite of ivabradine, or a pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients. The process comprises mixing or granulating the solid composite with one or more pharmaceutically acceptable excipients, followed by compression into tablets, using equipment and methods well-known to the skilled artisan. In an advantageous variant of the process of the present invention, the composite, in solution, was spray-dried onto one of the main excipients, e.g. the diluent, and the resulting granulate/blend was mixed with one or more pharmaceutically acceptable excipients, followed by compression into tablets.
The pharmaceutical composition in accordance with the present invention may be used as a medicament. The pharmaceutical composition typically may be used in the treatment of stable angina pectoris and chronic heart failure.
The present invention is illustrated by the following Examples.
EXAMPLES
Example 1, ivabradine hydrochloride: Eudragit® E PO (weight ratio 1:1)
5.16 g of ivabradine hydrochloride was dissolved in 41.50 g of ethanol (96%). 5.16 g of Eudragit® E PO was added. The solution was spray-dried on 134.43 g of microcrystalline cellulose. The resulting granulate/blend was sieved and 4.50 g of croscarmellose sodium was added by mixing, followed by the addition of 0.75 g magnesium stearate. The powder blend was compacted into tablets. Tablets with a total weight of 240 mg, containing 7.5 mg of ivabradine (referring to the amount of free base) were obtained.
The XRPD patterns of the tablets do not show any reflections in accordance with crystalline ivabradine hydrochloride. XRPD analysis performed 1 week after subjecting the tablets in open dish to 55°C/90% RH and 1 month to 40°C /75% RH showed that the tablets still do not show any reflections in accordance with crystalline ivabradine hydrochloride.
Tablets showed a fast dissolution at pH 1.2, 4.5 and 6.8.
Example 2, ivabradine hydrochloride: Eudragit® E PO (weight ratio 1:2)
5.16 g of ivabradine hydrochloride was dissolved in 75.00 g of ethanol (96%). 10.33 g of Eudragit® E PO was added. The solution was spray-dried on 129.26 g of microcrystalline cellulose. The resulting granulate/blend was sieved and 4.50 g of croscarmellose sodium was added by mixing, followed by the addition of 0.75 g magnesium stearate. The powder blend
was compacted into tablets. Tablets with a total weight of 240 mg, containing 7.5 mg of ivabradine (referring to the amount of free base) were obtained.
The XRPD patterns of the tablets do not show any reflections in accordance with crystalline ivabradine hydrochloride. XRPD analysis performed 1 week after subjecting the tablets in open dish to 55°C/90 RH and 1 month in alu/alu packaging to 40°C /75 RH showed that the tablets still do not show any reflections in accordance with crystalline ivabradine hydrochloride.
Tablets showed a fast dissolution at pH 1.2, 4.5 and 6.8. Example 3, ivabradine hydrochloride: Eudragit® E PO (weight ratio 1:5)
5.16 g of ivabradine hydrochloride was dissolved in 185.00 g of ethanol (96%). 25.80 g of Eudragit® E PO was added. The solution was spray-dried on 113.81 g of microcrystalline cellulose. The resulting granulate/blend was sieved and 4.50 g of croscarmellose sodium was added by mixing, followed by the addition of 0.75 g magnesium stearate. The powder blend was compacted into tablets. Tablets with a total weight of 240 mg, containing 7.5 mg of ivabradine (referring to the amount of free base) were obtained.
The XRPD patterns of the tablets do not show any reflections in accordance with crystalline ivabradine hydrochloride. XRPD analysis performed 1 week after subjecting the tablets in open dish to 55°C/90% RH and 1 month to 40°C /75% RH showed that the tablets still do not show any reflections in accordance with crystalline ivabradine hydrochloride.
Tablets showed a fast dissolution at pH 4.5 and 6.8.
Example 4, ivabradine hydrochloride:Amberlite® composites
Several solid composites comprising ivabradine hydrochloride were prepared using different types of Amberlite® as depicted in table 1.
Table 1
The composites were prepared by making a slurry of ivabradine hydrochloride and Amberlite® in water. The pH of the slurry was adjusted with either 0.1 M aqueous sodium hydroxide or 2.0 M aqueous hydrochloride to either 4-5 or 6-8 (see table 1). The slurries were stirred at ambient temperature over night. The composite was isolated by filtration, washed with water and dried at air.
XRPD data showed that the isolated composites are fully amorphous. Example 4, ivabradine hydrochloride: Amberlite® IRP64 (weight ratio 1:3)
Tablets were prepared with the ivabradine hydrochloride:Amberlite® IRP64 (weight ratio 1:3) solid composite, obtained as described in example 3. The composition of the tablets is shown in table 2.
Table 2
Ingredient %
Ivabradine hydrochloride: Amberlite® IRP64 (weight ratio 1:3) 15.0
Lactose monohydrate granulate (Supertab 30 GR) 64.0
Pregelatinized starch (Starch 1500) 20.0
Aerosil 200 VV 0.5
Magnesium stearate 0.5
Total 100.0
The solid composite of ivabradine hydrochloride: Amberlite® IRP64 (weight ratio 1:3) was mixed with Aerosil 200 VV and part of the lactose monohydrate granulate (Supertab 30 GR) for 10 minutes in a Turbula mixer at 22 rpm. The pre-mix was sieved over a 0.5 mm sieve. Pregelatinized starch (Starch 1500) and the rest of the lactose monohydrate granulate (Supertab 30 GR) were added and mixing was continued for 10 minutes. Magnesium stearate was sieved over a 0.6 mm sieve, added and mixed for 3 minutes at 22 rpm. Tablets were compressed.
Claims
1. A pharmaceutical composition comprising a solid composite of ivabradine, or a
pharmaceutically acceptable salt thereof, and an acrylate (co)polymer and one or more pharmaceutically acceptable excipients.
2. The composition according to claim 1, wherein the acrylate (co)polymer is a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate with a ratio of 2: 1 : 1.
3. The composition according to claim 1, wherein the acrylate (co)polymer is a copolymer of methacrylic acid and divinylbenzene.
4. The composition according to any one of claims 1 to 3, wherein the weight ratio of ivabradine, or a pharmaceutically acceptable salt thereof, to the acrylate (co)polymer ranges from 1: 1 to 1:8.
5. The composition according to any one of claims 1 to 4 comprising the hydrochloric acid salt of ivabradine.
6. The composition according to any one of claims 1 to 5, wherein ivabradine, or a
pharmaceutically acceptable salt thereof, is in an amorphous form.
7. The composition according to any one of claims 1 to 6, wherein the pharmaceutical composition is a tablet and the pharmaceutically acceptable excipients are one or more binders, diluents, disintegrants, glidants, lubricants, stabilizers, surface active agents or pH-adjusting agents.
8. The solid composite according to any one of claims 1 to 7.
9. A process for preparing the solid composite according to any one of claims 1 to 7
comprising combining ivabradine, or a pharmaceutically acceptable salt thereof, with an acrylate (co)polymer in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s).
10. The process according to claim 9, wherein the solvent is a polar solvent selected from the group consisting of alcohols, ethers, ketones, acetonitrile and water or a mixture thereof.
11. The solid composite according to any of claim 1 to 7 obtained by a process according to claim 10 or 11.
12. The process according to claim 10 or 11 further comprising mixing or granulating the solid composite with one or more pharmaceutically acceptable excipients, followed by compression into tablets.
13. The composition according to any one of claims 1 to 8, for use as a medicament.
14. The composition according to claim 14 for use in the treatment of stable angina pectoris and chronic heart failure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14815382.8A EP3082772A1 (en) | 2013-12-20 | 2014-12-19 | Pharmaceutical composition comprising amorphous ivabradine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199129 | 2013-12-20 | ||
| EP13199129.1 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015091992A1 true WO2015091992A1 (en) | 2015-06-25 |
Family
ID=49882907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2014/078819 WO2015091992A1 (en) | 2013-12-20 | 2014-12-19 | Pharmaceutical composition comprising amorphous ivabradine |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3082772A1 (en) |
| WO (1) | WO2015091992A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145234A1 (en) * | 2014-03-27 | 2015-10-01 | Laboratorio Chimico Internazionale S.P.A. | Ivabradine adsorbates |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040028743A1 (en) * | 2000-12-26 | 2004-02-12 | Patrick Wuthrich | Solid themoformable pharmaceutical composition for the controlled release of ivabradine |
| WO2010128525A2 (en) * | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
| WO2011098582A2 (en) * | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
-
2014
- 2014-12-19 EP EP14815382.8A patent/EP3082772A1/en not_active Withdrawn
- 2014-12-19 WO PCT/EP2014/078819 patent/WO2015091992A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040028743A1 (en) * | 2000-12-26 | 2004-02-12 | Patrick Wuthrich | Solid themoformable pharmaceutical composition for the controlled release of ivabradine |
| WO2010128525A2 (en) * | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
| WO2011098582A2 (en) * | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145234A1 (en) * | 2014-03-27 | 2015-10-01 | Laboratorio Chimico Internazionale S.P.A. | Ivabradine adsorbates |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3082772A1 (en) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2684977C (en) | A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant | |
| US20240075039A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| US20090324718A1 (en) | Imatinib compositions | |
| EP2732810A1 (en) | Spherical particles of clopidogrel bisulfate, pharmaceutical composition including same, and method for manufacturing same | |
| US10507204B2 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
| JP5993965B2 (en) | Stable tablet containing solifenacin and method for producing the same | |
| WO2015001133A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
| WO2007049868A1 (en) | Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate | |
| EP3082772A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
| EP3073996A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
| WO2007134845A2 (en) | Olanzapine pharmaceutical composition | |
| JP7245694B2 (en) | Pharmaceutical composition containing linagliptin, method for producing the same, and method for improving quality of pharmaceutical composition containing linagliptin | |
| WO2014095818A1 (en) | Formulation comprising amorphous agomelatine | |
| WO2014198342A1 (en) | Pharmaceutical composition comprising amorphous sunitinib | |
| WO2014013090A2 (en) | Formulation comprising amorphous fingolimod | |
| KR101977890B1 (en) | Stable pharmaceutical composition comprising solifenacin, and method for preparing the same | |
| US20090214646A1 (en) | Pharmaceutical formulations containing clopidogrel | |
| WO2015124496A1 (en) | Pharmaceutical composition comprising amorphous agomelatine | |
| CN112057427A (en) | Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof | |
| KR102322429B1 (en) | Oral formulation containing sunitinib and the method for preparing the same | |
| EP3233082A1 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
| KR20150115803A (en) | Pharmacutical compositions containing dexketoprofen and tramadol | |
| KR20210077626A (en) | Oral solid formulation comprising sunitinib hydrochloride salt and method for preparing the same | |
| KR100910306B1 (en) | Wetgranulation composition containg Sibutramine free base | |
| KR20210049583A (en) | Preparation of Sorafenib Tosylate Salt with Improved Productivity and Elution Property, and Method for Preparing the Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14815382 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2014815382 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2014815382 Country of ref document: EP |